0000950170-23-054407.txt : 20231020 0000950170-23-054407.hdr.sgml : 20231020 20231020164450 ACCESSION NUMBER: 0000950170-23-054407 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231020 FILED AS OF DATE: 20231020 DATE AS OF CHANGE: 20231020 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Connect Biopharma Holdings Ltd CENTRAL INDEX KEY: 0001835268 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40212 FILM NUMBER: 231337540 BUSINESS ADDRESS: STREET 1: 12265 EL CAMINO REAL, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-727-1040 MAIL ADDRESS: STREET 1: 12265 EL CAMINO REAL, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92130 6-K 1 cntb_6k_20231020.htm 6-K 6-K

 

 

 

 

 

 

 

 

 

 

UNITED STATES

 

 

SECURITIES AND EXCHANGE COMMISSION

 

 

Washington, D.C. 20549

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FORM 6-K

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

 

 

PURSUANT TO RULE 13a-16 OR 15d-16

 

 

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

 

 

 

 

 

 

For the month of October 2023

 

 

 

 

 

 

 

 

 

Commission File Number: 001-40212

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Connect Biopharma Holdings Limited

 

 

(Translation of registrant's name into English)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

12265 El Camino Real, Suite 350

 

 

San Diego, CA 92130, USA

 

 

(Address of principal executive office)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

 

 

 

 

 

 

 

 

Form 20-F ☒ Form 40-F ☐

 

 

 

 

 

 

 

 

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

 

 

 

 

 

 

 

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

 

 

 

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

 

On October 18, 2023, Derek DiRocco, Ph.D. tendered his resignation as a director of Connect Biopharma Holdings Limited (the “Company”), effective October 18, 2023. Dr. DiRocco’s resignation is not the result of any disagreement with the Company, including but not limited to, on any matter related to its operations, policies or practices.

 

This Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File No. 333-264340) and Form S-8 (File Nos. 333-254254 and 333-266006) of the Company, filed with the Securities and Exchange Commission, and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

 

 

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Dated: October 20, 2023

 

 

 

 

 

 

 

 

CONNECT BIOPHARMA HOLDINGS LIMITED

 

 

By

 

/s/ Steven Chan

 

 

 

 

Name:

 

Steven Chan

 

 

 

 

Title:

 

Chief Financial Officer